左乙拉西坦、磷苯妥英与丙戊酸治疗已确立癫痫持续状态的疗效(ESETT):一项双盲、响应适应性、随机对照试验
ESETT是一项在美国58家医院急诊科开展的多中心、双盲、响应适应性随机对照试验,纳入478例(462例独特患者)年龄≥2岁、经足量苯二氮卓类治疗后仍持续或复发全面性惊厥5-30分钟的已确立癫痫持续状态患者,按年龄组(<18岁、18-65岁、>65岁)分层随机分配至左乙拉西坦、磷苯妥英或丙戊酸。主要终点为开始输注药物后1小时无临床明显癫痫发作且意识改善、未追加抗癫痫药物。各年龄组内三种药物的疗效和主要安全性结局(危及生命的低血压或心律失常)均无差异;除儿童气管插管外,次要安全性结局在各年龄组内无显著差异。作者结论认为三种药物均可考虑作为苯二氮卓难治性癫痫持续状态的二线首选药物。
要点
- 各年龄组内左乙拉西坦、磷苯妥英、丙戊酸的疗效无差异,主要终点达标率约半数。
- 儿童左乙拉西坦52%、磷苯妥英49%、丙戊酸52%;成人分别为44%、46%、46%;老年分别为37%、35%、47%。
- 主要安全性结局(危及生命的低血压或心律失常)在各年龄组内三种药物间无差异。
- 除儿童气管插管外,次要安全性结局在各年龄组内无显著差异。
- 作者认为三种药物均可考虑作为苯二氮卓难治性癫痫持续状态的二线首选药物。
适用人群与场景
- 年龄≥2岁,全面性惊厥发作持续>5分钟且已接受足量苯二氮卓类治疗,在急诊科最后一次苯二氮卓类给药后仍持续或复发惊厥至少5分钟且不超过30分钟的患者。
- 按年龄分层:<18岁、18-65岁、>65岁。
诊断标准与关键阈值
- 已确立癫痫持续状态:全面性惊厥发作>5分钟,经足量苯二氮卓类治疗后仍持续或复发惊厥5-30分钟。
处置流程与药物剂量
- 按年龄组(<18岁、18-65岁、>65岁)分层,采用贝叶斯方法响应适应性随机分配至左乙拉西坦、磷苯妥英或丙戊酸。
- 主要终点评估时间:开始药物输注后1小时。
红旗征与不能漏的情况
- 危及生命的低血压或心律失常为主要安全性结局,各年龄组内三种药物间无差异。
研究设计与关键结果
- 多中心、双盲、响应适应性随机对照试验,美国58家医院急诊科,纳入478例患者,462例独特患者纳入分析:儿童(<18岁)225例、成人(18-65岁)186例、老年(>65岁)51例。
- 随机分配:左乙拉西坦175例(38%)、磷苯妥英142例(31%)、丙戊酸145例(31%)。
- 主要疗效终点(开始输注后1小时无临床明显癫痫发作、意识改善且未追加抗癫痫药物)达标率:儿童左乙拉西坦52%(95%可信区间41-62)、磷苯妥英49%(38-61)、丙戊酸52%(41-63);成人左乙拉西坦44%(33-55)、磷苯妥英46%(34-59)、丙戊酸46%(34-58);老年左乙拉西坦37%(19-59)、磷苯妥英35%(17-59)、丙戊酸47%(25-70)。
- 各年龄组内三种药物的疗效和主要安全性结局均无差异。
- 除儿童气管插管外,次要安全性结局在各年龄组内三种药物间无显著差异。
证据类型、等级与局限
- 证据类型:多中心、双盲、响应适应性随机对照试验。
- 作者结论:儿童、成人和老年已确立癫痫持续状态患者对左乙拉西坦、磷苯妥英和丙戊酸的反应相似,约半数患者治疗成功;三种药物均可考虑作为苯二氮卓难治性癫痫持续状态的二线首选药物。
对床旁实践的改变
- 对于年龄≥2岁、苯二氮卓难治性全面性惊厥性癫痫持续状态患者,左乙拉西坦、磷苯妥英或丙戊酸均可考虑作为二线首选药物(作者认为)。
- 各年龄组内三种药物疗效和主要安全性无差异,选择时可综合考虑其他因素。
指南或共识出处
- ESETT试验注册号ClinicalTrials.gov NCT01960075;资助:美国国家神经疾病与卒中研究所、美国国立卫生研究院。
提炼说明
- 本条依据论文摘要整理;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Benzodiazepine-refractory, or established, status epilepticus is thought to be of similar pathophysiology in children and adults, but differences in underlying aetiology and pharmacodynamics might differentially affect response to therapy. In the Established Status Epilepticus Treatment Trial (ESETT) we compared the efficacy and safety of levetiracetam, fosphenytoin, and valproate in established status epilepticus, and here we describe our results after extending enrolment in children to compare outcomes in three age groups.
METHODS: In this multicentre, double-blind, response-adaptive, randomised controlled trial, we recruited patients from 58 hospital emergency departments across the USA. Patients were eligible for inclusion if they were aged 2 years or older, had been treated for a generalised convulsive seizure of longer than 5 min duration with adequate doses of benzodiazepines, and continued to have persistent or recurrent convulsions in the emergency department for at least 5 min and no more than 30 min after the last dose of benzodiazepine. Patients were randomly assigned in a response-adaptive manner, using Bayesian methods and stratified by age group (<18 years, 18-65 years, and >65 years), to levetiracetam, fosphenytoin, or valproate. All patients, investigators, study staff, and pharmacists were masked to treatment allocation. The primary outcome was absence of clinically apparent seizures with improved consciousness and without additional antiseizure medication at 1 h from start of drug infusion. The primary safety outcome was life-threatening hypotension or cardiac arrhythmia. The efficacy and safety outcomes were analysed by intention to treat. This study is registered in ClinicalTrials.gov, NCT01960075.
FINDINGS: Between Nov 3, 2015, and Dec 29, 2018, we enrolled 478 patients and 462 unique patients were included: 225 children (aged <18 years), 186 adults (18-65 years), and 51 older adults (>65 years). 175 (38%) patients were randomly assigned to levetiracetam, 142 (31%) to fosphenyltoin, and 145 (31%) were to valproate. Baseline characteristics were balanced across treatments within age groups. The primary efficacy outcome was met in those treated with levetiracetam for 52% (95% credible interval 41-62) of children, 44% (33-55) of adults, and 37% (19-59) of older adults; with fosphenytoin in 49% (38-61) of children, 46% (34-59) of adults, and 35% (17-59) of older adults; and with valproate in 52% (41-63) of children, 46% (34-58) of adults, and 47% (25-70) of older adults. No differences were detected in efficacy or primary safety outcome by drug within each age group. With the exception of endotracheal intubation in children, secondary safety outcomes did not significantly differ by drug within each age group.
INTERPRETATION: Children, adults, and older adults with established status epilepticus respond similarly to levetiracetam, fosphenytoin, and valproate, with treatment success in approximately half of patients. Any of the three drugs can be considered as a potential first-choice, second-line drug for benzodiazepine-refractory status epilepticus.
FUNDING: National Institute of Neurological Disorders and Stroke, National Institutes of Health.
参考来源
- Chamberlain JM, Kapur J, Shinnar S, et al. Efficacy of levetiracetam, fosphenytoin, and valproate for established status epilepticus by age group (ESETT): a double-blind, responsive-adaptive, randomised controlled trial. Lancet. 2020. PMID: 32203691. doi:10.1016/S0140-6736(20)30611-5
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。